Experienced in Bursitis

Rainer Fietkau

Erlangen, BY, DE 
Experienced in Bursitis
Erlangen, BY, DE 
OverviewLocationsClinical Research

Overview

Rainer Fietkau practices in Erlangen, Germany. Mr. Fietkau is rated as an Experienced expert by MediFind in the treatment of Bursitis. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Glioblastoma, Colorectal Cancer, Mastectomy, and Pancreatectomy.

His clinical research consists of co-authoring 509 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Bursitis.

Gender
Male

Locations

Erlangen, BY, Germany
Other Locations
Regensburg, BY, Germany
Munich, BY, Germany
Alexander, NW, Germany
Bayern, BY, Germany
Department Of Otorhinolaryngology Head And Neck Surgery, Nuernberg, BY, Germany
Frankfurt Am Main, HE, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Significance of Chemoradiation Following Induction Chemotherapy in Locally Advanced,Unresectable Pancreatic Cancer -a Randomised Phase 3 Trial: Chemoradiation Following Induction Chemotherapy Compared With Chemotherapy Alone
Significance of Chemoradiation Following Induction Chemotherapy in Locally Advanced,Unresectable Pancreatic Cancer -a Randomised Phase 3 Trial: Chemoradiation Following Induction Chemotherapy Compared With Chemotherapy Alone
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug, Radiation
Study Drugs: Gemcitabine, FOLFIRINOX
Study Phase: Phase 3
A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: December 20, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Postoperative Radiotherapy of Non-small Cell Lung Cancer: Accelerated vs. Conventional Fractionation
Postoperative Radiotherapy of Non-small Cell Lung Cancer: Accelerated vs. Conventional Fractionation
Enrollment Status: Completed
Publish Date: July 22, 2020
Intervention Type: Radiation
Study Phase: Not Applicable
View 2 Less Clinical Trials

509 Total Publications

DEGRO statement on the FAST-Forward trial: 10-year data of ultrahypofractionated radiation therapy for breast cancer.
DEGRO statement on the FAST-Forward trial: 10-year data of ultrahypofractionated radiation therapy for breast cancer.
Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
Published: October 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fietkau's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 53 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile